Pentoxifylline in the Treatment of Intermittent Claudication of the Lower Limbs

Reich, Theobald; Cutler, Bruce C.; Lee, Bok Y.; Porter, John M.; Reichle, Frederick A.; Scogin, John T.; Strandness, D. Eugene
July 1984
Angiology;Jul1984, Vol. 35 Issue 7, p389
Academic Journal
Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily, increased stepwise to 1200 mg daily at the end of one month) and 40 who took placebo for 24 weeks. Twenty-five patients on pentoxifylline and 21 on placebo were dropped from the study for reasons unrelated to the drug. Walking ability on a treadmill was increased significantly after 2 weeks and remained so throughout the study in the pentoxifylline vs. the placebo group. Ability to walk until first experiencing intermittent claudication was a more sensitive index than the maximum ability to walk. The drug did not cause changes in blood pressure or in heart rate. Other than mild nausea, there were no significant side effects.


Related Articles

  • Silence of the Limbs: Pharmacological Symptomatic Treatment of Intermittent Claudication. De Backer, Tine; Vander Stichele, Robert; De Buyzere, Marc; De Backer, Guy; Van Bortel, Lucas // Current Vascular Pharmacology;May2010, Vol. 8 Issue 3, p383 

    Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules. Although spanning several decades, several studies underlying these claims were not...

  • Placebo Controlled Double Blind Study with Pentoxifylline of Walking Performance in Patients with Intermittent Claudication. Di Perri, Tullio; Guerrini, Maurizio // Angiology;Jan1983, Vol. 34 Issue 1, p40 

    A double blind placebo-controlled randomised crossover study was performed with Pentoxifylline (Trental 400 tablets with 400 mg active ingredient) in 24 patients (19 males, 5 females, aged between 40 and 71 years) suffering from peripheral occlusive arteriopathy of stage II severity (Fontaine's...

  • Acenocoumarol and Pentoxifylline in Intermittent Claudication. A Controlled Clinical Study. Dettori, Anton G.; Pini, Mario; Moratti, Alfio; Paolicelli, Mauro; Basevi, Paolo; Quintavalla, Roberto; Manotti, Cesare; Di Lecce, Carmelo // Angiology;Apr1989 Part 1, Vol. 40 Issue 4, p237 

    The efficacy and safety of pentoxifylline (400 mg tid orally) and acenocoumarol, administered singly or in combination, in the treatment of intermittent claudication associated with chronic occlusive arterial disease were evaluated in a multi-center, randomized, factorial, blind clinical trial...

  • The Effectiveness of Isoxsuprine in Patients With Intermittent Claudication. Skotnicki, S. H.; van Gaal, G.; Wijn, P. F. F. // Angiology;Nov1984, Vol. 35 Issue 11, p685 

    Sixty male patients with intermittent claudication were investigated in a randomized, double-blind, placebo-controlled study in order to determine the effectiveness of Isoxsuprine. The analysis of the results was made on the basis of subjective assessment of symptoms by the patients themselves...

  • Placebo-Controlled, Double-Blind Study of the Effect of Verapamil in Intermittent Claudication. Kimose, Hans-Henrik; Bagger, Jens Peder; Aagaard, Michael Trier; Paulsen, Peter Kildeberg // Angiology;Aug1990, Vol. 41 Issue 8, p595 

    The clinical effect of verapamil was tested in 24 patients with intermittent claudication in a randomized, placebo-controlled, double-blind, crossover study. Slow-release verapamil or placebo was given for two periods of three weeks. The walking distance, systemic blood pressure, and...

  • Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication. Perhoniemi, Vesa; Salmenkivi, Kari; Sundberg, Stig; Johnsson, Riitta; Gordin, Ariel // Angiology;Jun1984, Vol. 35 Issue 6, p366 

    Thirty-one patients, mean age 60 years (range 45–80 years), with a typical history and objective symptoms of intermittent claudication with a reported maximal walking distance less than 500 m. were included in a cross-over study. After a one month's run-in period on placebo, the patients...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...

  • Pentoxifylline for Intermittent Claudication. Ernst, E. // Angiology;May1994, Vol. 45 Issue 5, p339 

    Pentoxifylline was first introduced in Germany twenty years ago. Today it is the best researched oral drug for intermittent claudication. A total of seventeen placebo-controlled trials could be retrieved from the world literature. The majority of these studies show that pentoxifylline will...

  • The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients. Huisinga, Jessie M.; Pipinos, Iraklis I.; Johanning, Jason M.; Stergiou, Nicholas // Journal of NeuroEngineering & Rehabilitation (JNER);2010, Vol. 7, p25 

    Background: Pharmacological treatment has been advocated as a first line therapy for Peripheral Arterial Disease (PAD) patients suffering from intermittent claudication. Previous studies document the ability of pharmacological treatment to increase walking distances. However, the effect of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics